Effective antimicrobial activity of Cbf-14-2 against penicillin-resistant bacteria<i> in vitro</i> and<i> in vivo</i>

WANG Mengxiao; MA Lingman; LIU Hanhan; JIANG Meiling; DOU Jie; ZHOU Changlin

doi:10.11665/j.issn.1000-5048.20170416

Journal of China Pharmaceutical University > 2017 > 48(4): 496-502. > DOI: 10.11665/j.issn.1000-5048.20170416

WANG Mengxiao, MA Lingman, LIU Hanhan, JIANG Meiling, DOU Jie, ZHOU Changlin. Effective antimicrobial activity of Cbf-14-2 against penicillin-resistant bacteria in vitro and in vivo[J]. Journal of China Pharmaceutical University, 2017, 48(4): 496-502. DOI: 10.11665/j.issn.1000-5048.20170416

Citation:

PDF (2845 KB)

Effective antimicrobial activity of Cbf-14-2 against penicillin-resistant bacteria in vitro and in vivo

More Information

Graphical Abstract

Abstract

Abstract

The antibacterial activity and mechanism of the antimicrobial peptide mutant Cbf-14-2 against NDM-1 carrying recombinant bacteria(E. coli BL21(DE3)-NDM-1)was investigated in this study. The minimum inhibitory concentration(MIC), minimum bactericidal concentration(MBC)and killing curves(KCs) in vitro were determined by the broth microdilution method. Mice septicemia model was established by interaperitotoneal injection of E. coli BL21(DE3)-NDM-1 to evaluate the antibacterial activity of this peptide in vivo. Results showed that Cbf-14-2 exhibited a potent antibacterial activity with MIC of 16 μg/mL and killed almost all recombinant bacteria within 120 min. Meanwhile, it significantly improved the survival rate of infected mice up to 70% with the decreasing of bacterial load in mice lung, liver, spleen and kidney. This powerful clearance ability of Cbf-14-2 against bacteria mainly related to its enhanced membrane penetration ability through neutralizing the negative charges and disrupting the integrity of the bacterial cell membrane. Therefore, Cbf-14-2 is expected to be a potential antimicrobial agent for the treatment of infection induced by multi-drug resistant bacteria, especially for the NDM-1carrying bacteria.
- antimicrobial peptide,
- Cbf-14-2,
- antimicrobial activity,
- NDM-1

FullText(HTML)

References (18)

References

[1]	Molton JS, Tambyah PA, Ang BS, et al. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia[J].Clin Infect Dis,2013,56(9):1310-1318.
[2]	Nordmann P,Poirel L,Walsh TR,et al.The emerging NDM carbapenemases[J].Trends Microbiol,2011,19(12):588-595.
[3]	Dortet L,Nordmann P,Poirel L.Association of the emerging carbapenemase NDM-1 with a bleomycin resistance protein in Enterobacteriaceae and Acinetobacter baumannii[J].Antimicrob Agents Chemother,2012,56(4):1693-1697.
[4]	Tangden T,Giske CG.Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae:clinical perspectives on detection,treatment and infection control[J].J Intern Med,2015,277(5):501-512.
[5]	Wailan AM,Paterson DL.The spread and acquisition of NDM-1: a multifactorial problem[J].Expert Rev Anti Infect Ther,2014,12(1):91-115.
[6]	Jin L,Bai XW,Luan N,et al.A Designed tryptophan- and lysine/arginine-rich antimicrobial peptide with therapeutic potential for clinical antibiotic-resistant Candida albicans Vaginitis[J].J Med Chem,2016,59(5):1791-1799.
[7]	Li B,Li B,Tian YW,et al.The anti-biofilm activity against drug-resistance bacterial of antimicrobial peptide BF-30 in vitro[J].Pharm Biotechnol,2015,22(1):14-19.
[8]	Li SA,Lee WH,Zhang Y.Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models[J].Antimicrob Agents Chemother,2012,56(6):3309-3317.
[9]	Ma LM,Wang YR,Wang MX,et al.Effective antimicrobial activity of Cbf-14,derived from a cathelin-like domain,against penicillin-resistant bacteria[J].Biomaterials,2016,87:32-45.
[10]	Hao QR,Wang H,Wang J,et al.Effective antimicrobial activity of Cbf-K₁₆ and Cbf-A₇A₁₃ against NDM-1-carrying Escherichia coli by DNA binding after penetrating thecytoplasmic membrane in vitro[J].J Pept Sci,2013,19(3):173-180.
[11]	Butt TR,Edavettal SC,Hall JP,et al.SUMO fusion technology for difficult-to-express proteins[J].Prot Exp Purif,2005,43(1):1-9.
[12]	Giles FJ,Rodriguez R,Weisdorf D,et al.A phase III,randomized,double-blind,placebo-controlled,study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy[J].Leukemia Res,2004,28(6):559-565.
[13]	Machuca J,Ortiz M,Recacha E,et al.Impact of AAC(6′)-Ib-cr in combination with chromosomal-mediated mechanisms on clinical quinolone resistance in Escherichia coli[J].J Antimicrob Chemother,2016,71(11):3066-3071.
[14]	Fomda BA,Khan A,Zahoor D.NDM-1(New Delhi metallo beta lactamase-1)producing gram-negative bacilli: emergence & clinical implications[J].Indian J Med Res,2014,140(5):672-678.
[15]	Fan HY,Nazari M,Raval G,et al.Utilizing zeta potential measurements to study the effective charge,membrane partitioning,and membrane permeation of the lipopeptide surfactin[J].Biochim Biophys Acta,2014,1838(9):2306-2312.
[16]	Yuan Q,He L,Ke H.A potential substrate binding conformation of β-lactams and insight into the broad spectrum of NDM-1activity[J].Antimicrob Agents Chemother,2012,56(10):5157-5163.
[17]	Brogden KA.Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria[J].Nat Rev Microbiol,2005,3(3):238-250.
[18]	Oren Z,Shai Y.Mode of action of linear amphipathic α-helical antimicrobial peptides[J].Pept Sci,1998,47(6):451-463.

Cited By

Get Citation

PDF

XML

Article views (895) PDF downloads (2398)

Turn off MathJax

Article Contents

Abstract

References

Effective antimicrobial activity of Cbf-14-2 against penicillin-resistant bacteria in vitro and in vivo

Abstract

References

Catalog

Export File

Citation

Format

Content